JP2020529410A - Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 - Google Patents

Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 Download PDF

Info

Publication number
JP2020529410A
JP2020529410A JP2020505208A JP2020505208A JP2020529410A JP 2020529410 A JP2020529410 A JP 2020529410A JP 2020505208 A JP2020505208 A JP 2020505208A JP 2020505208 A JP2020505208 A JP 2020505208A JP 2020529410 A JP2020529410 A JP 2020529410A
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable domain
binding site
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020505208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529410A5 (https=
Inventor
ピー． チャン グレゴリー
ピー． チャン グレゴリー
エフ． チェン アン
エフ． チェン アン
ヘイニー ウィリアム
ヘイニー ウィリアム
エム． ルンデ ブラッドリー
エム． ルンデ ブラッドリー
プリンズ ビアンカ
プリンズ ビアンカ
Original Assignee
ドラゴンフライ セラピューティクス， インコーポレイテッド
ドラゴンフライ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドラゴンフライ セラピューティクス， インコーポレイテッド, ドラゴンフライ セラピューティクス， インコーポレイテッド filed Critical ドラゴンフライ セラピューティクス， インコーポレイテッド
Publication of JP2020529410A publication Critical patent/JP2020529410A/ja
Publication of JP2020529410A5 publication Critical patent/JP2020529410A5/ja
Priority to JP2023075458A priority Critical patent/JP2023106433A/ja
Priority to JP2025092507A priority patent/JP2025131681A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
JP2020505208A 2017-07-31 2018-07-31 Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 Pending JP2020529410A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023075458A JP2023106433A (ja) 2017-07-31 2023-05-01 Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質
JP2025092507A JP2025131681A (ja) 2017-07-31 2025-06-03 Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539421P 2017-07-31 2017-07-31
US62/539,421 2017-07-31
PCT/US2018/044610 WO2019028027A1 (en) 2017-07-31 2018-07-31 PROTEINS BINDING TO NKG2D, CD16 AND FLT3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023075458A Division JP2023106433A (ja) 2017-07-31 2023-05-01 Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質

Publications (2)

Publication Number Publication Date
JP2020529410A true JP2020529410A (ja) 2020-10-08
JP2020529410A5 JP2020529410A5 (https=) 2021-09-24

Family

ID=65233032

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020505208A Pending JP2020529410A (ja) 2017-07-31 2018-07-31 Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質
JP2023075458A Pending JP2023106433A (ja) 2017-07-31 2023-05-01 Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質
JP2025092507A Pending JP2025131681A (ja) 2017-07-31 2025-06-03 Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023075458A Pending JP2023106433A (ja) 2017-07-31 2023-05-01 Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質
JP2025092507A Pending JP2025131681A (ja) 2017-07-31 2025-06-03 Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質

Country Status (15)

Country Link
US (1) US20200165344A1 (https=)
EP (1) EP3661554A4 (https=)
JP (3) JP2020529410A (https=)
KR (2) KR20200033302A (https=)
CN (1) CN111132698A (https=)
AU (2) AU2018309712A1 (https=)
BR (1) BR112020001972A2 (https=)
CA (1) CA3070986A1 (https=)
CO (1) CO2020001981A2 (https=)
EA (1) EA202090387A1 (https=)
IL (1) IL272374A (https=)
MA (1) MA49769A (https=)
MX (1) MX2020001257A (https=)
SG (1) SG11202000632QA (https=)
WO (1) WO2019028027A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201907299XA (en) 2017-02-08 2019-09-27 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
IL268755B2 (en) 2017-02-20 2025-12-01 Dragonfly Therapeutics Inc Proteins that bind her2, nkg2d, and cd16
EA202091887A1 (ru) 2018-02-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
MX2020010003A (es) 2018-03-27 2021-01-15 Xyphos Biosciences Inc Dominios a1-a2 modificados de ligandos nkg2d no naturales que se unen a receptores nkg2d no naturales.
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
JP7642542B2 (ja) 2018-12-18 2025-03-10 ベーリンガー・インゲルハイム・イオ・カナダ・インコーポレイテッド Ｆｌｔ３アゴニスト抗体及びその使用
MX2022004430A (es) * 2019-10-15 2022-07-19 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3).
CA3170833A1 (en) * 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
WO2023274183A1 (zh) * 2021-06-29 2023-01-05 江苏先声药业有限公司 Cd16抗体及其应用
WO2026052582A1 (en) 2024-09-04 2026-03-12 Red Ridge Bio Ag Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506406A (ja) * 2007-12-14 2011-03-03 ノボ・ノルデイスク・エー／エス ヒトｎｋｇ２ｄに対する抗体とその使用
JP2011521647A (ja) * 2008-05-30 2011-07-28 イムクローン・リミテッド・ライアビリティ・カンパニー 抗ｆｌｔ３抗体
JP2013500721A (ja) * 2009-07-29 2013-01-10 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
JP2013515472A (ja) * 2009-12-23 2013-05-09 シュニムネ ゲーエムベーハー 抗ｆｌｔ３抗体及びその使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
LT2794658T (lt) * 2011-12-19 2017-05-10 Synimmune Gmbh Bispecifinė antikūno molekulė
EP4310191A3 (en) * 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
EP3126384B1 (en) * 2014-04-01 2020-12-02 Adimab, LLC Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
WO2016166139A1 (en) * 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506406A (ja) * 2007-12-14 2011-03-03 ノボ・ノルデイスク・エー／エス ヒトｎｋｇ２ｄに対する抗体とその使用
JP2011521647A (ja) * 2008-05-30 2011-07-28 イムクローン・リミテッド・ライアビリティ・カンパニー 抗ｆｌｔ３抗体
JP2013500721A (ja) * 2009-07-29 2013-01-10 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
JP2013515472A (ja) * 2009-12-23 2013-05-09 シュニムネ ゲーエムベーハー 抗ｆｌｔ３抗体及びその使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUMAN VACCINES & IMMUNOTHERAPEUTICS, vol. 12, no. 11, JPN6021051696, 2016, pages 2790 - 2796, ISSN: 0004959289 *
ファルマシア, vol. 51, no. 5, JPN6021051695, 2015, pages 424 - 428, ISSN: 0004959290 *

Also Published As

Publication number Publication date
BR112020001972A2 (pt) 2020-08-04
AU2018309712A1 (en) 2020-02-13
KR20200033302A (ko) 2020-03-27
AU2025204591A1 (en) 2025-07-10
MA49769A (fr) 2021-04-21
CO2020001981A2 (es) 2020-05-29
WO2019028027A1 (en) 2019-02-07
CN111132698A (zh) 2020-05-08
EP3661554A4 (en) 2021-04-21
US20200165344A1 (en) 2020-05-28
EP3661554A1 (en) 2020-06-10
IL272374A (en) 2020-03-31
MX2020001257A (es) 2020-08-17
JP2023106433A (ja) 2023-08-01
EA202090387A1 (ru) 2020-05-21
CA3070986A1 (en) 2019-02-07
SG11202000632QA (en) 2020-02-27
JP2025131681A (ja) 2025-09-09
KR20250051800A (ko) 2025-04-17

Similar Documents

Publication Publication Date Title
JP7431392B2 (ja) ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質
US20210261668A1 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
JP7257323B2 (ja) Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質
JP2025061059A (ja) Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質
US20200277384A1 (en) Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1)
JP2023106433A (ja) Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質
US20200157174A1 (en) Proteins binding nkg2d, cd16 and ror1 or ror2
JP2023030174A (ja) Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質
JP2024012297A (ja) Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質
JP2020508997A (ja) Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質
JP2022105121A (ja) Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質
JP2020510644A (ja) Ｇｄ２、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質
JP2021523140A (ja) Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合するタンパク質
JP2020508998A (ja) Ｃｄ１２３、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質
HK40062610A (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210729

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210729

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230110